Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

Patient Flow in Hepatitis C Virus: Changing Treatment Dynamics in an Interferon-Free World 7/18/2012 \| published by: Decision Resources ... is very complex owing to a large undiagnosed population, high frequency of spontaneous viral clearance - which complicates epidemiological data collection and analysis - an aging cohort effect, and the circulation of numerous HCV genotypes ... \| read more...	$15,000.00
Fibromyalgia 7/16/2012 \| published by: Decision Resources ... from which fibromyalgia patients suffer. Heterogeneity in the fraction of patients who respond to a given therapy—and in the magnitude of that response—drives frequent treatment changes and additions. As a result, current treatment of this ... \| read more...	$15,000.00
Non-Small-Cell Lung Cancer in China 7/16/2012 \| published by: Decision Resources ... and a burgeoning middle class with growing economic clout, these factors promise double-digit growth and significant opportunity for multinational pharmaceutical companies. Please note, the PDF e-mail from publisher version of this report is for a ... \| read more...	$15,000.00
PatientTrends®: Rheumatoid Arthritis (EU) 2012 7/16/2012 \| published by: Decision Resources ... diagnosis and look at what drives patient satisfaction with their physician and their therapeutic regimen. This report will also examine how patients seek out information about their disease and what product attributes would encourage patients ... \| read more...	$10,000.00
Biosimilars Advisory Service: U.S. AND E.U. Payer Perspectives 7/15/2012 \| published by: Decision Resources ... primary research and forecasting modules are all included in a subscription to the Biosimilars Advisory Service. Rely on BioTrends to keep you up-to-date on the biosimilars landscape and poised to maximize opportunities for your business. ... \| read more...	$10,000.00
LaunchTrends®: Peginesatide (Omontys)(Anemia ESRD)(Wave 1) 2012 7/13/2012 \| published by: Decision Resources ... room for a fourth product? LaunchTrends® are a series of four syndicated reports that track the trial, adoption, and usage during a Omontys’ initial market introduction. Fielding occurs at one, three, six and twelve months ... \| read more...	$15,000.00
Oral Therapies for Type 2 Diabetes: Physician and Payer Perspectives on Market Dynamics in Brazil and Mexico 7/12/2012 \| published by: Decision Resources ... the burden of type 2 diabetes grows in these emerging markets, so does the demand for better access to care, thereby presenting new opportunities for manufacturers of oral antidiabetic agents (OAAs). Several DPP-IV inhibitors have ... \| read more...	$10,000.00
PatientTrends®: Crohn's Disease 2012 7/2/2012 \| published by: Decision Resources ... look at what drives patients’ satisfaction with their current crohn’s disease (CD) treatment, especially with regards to biologics, and identify what treatment attributes are most likely to prompt a patient to request a switch to ... \| read more...	$10,000.00
TreatmentTrends®: MRSA and Serious Gram-Positive Infections (US) 2012 6/30/2012 \| published by: Decision Resources ... clinically-important Gram-positive pathogens, such as CA-MRSA, HA-MRSA, VISA, VRSA, and VRE. TreatmentTrends® is a syndicated report series that provides longitudinal information on market dynamics, including insight into practice pat-terns, attitudes and perceptions, unmet needs, and ... \| read more...	$15,000.00
TreatmentTrends®: Rheumatoid Arthritis (Wave 2) US 2012 6/29/2012 \| published by: Decision Resources ... patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs. TreatmentTrends® are syndicated report series that provide longitudinal information ... \| read more...	$15,000.00
PatientTrends®: Lupus 2012 6/29/2012 \| published by: Decision Resources ... their physician and their therapeutic regimen. This report will also examine how patients seek out information about their disease and what product attributes would encourage patients to seek a switch in therapies, particularly a new ... \| read more...	$10,000.00
TreatmentTrends®: Chronic Kidney Disease (Wave 1) US 2012 6/29/2012 \| published by: Decision Resources ... key details on how U.S. patients in all Stages of Chronic Kidney Disease (CKD) are managed: early disease (Stage 1 and 2), mid-stage disease (Stage 3) and late-stage disease (Stage 4 and 5 not on ... \| read more...	$15,000.00
TreatmentTrends®: US Nephrology (BMM & Anemia)(Wave 2) 2012 6/28/2012 \| published by: Decision Resources ... (vitamin D and calcimimetic agents). TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. They ... \| read more...	$15,000.00
LaunchTrends®: Abiraterone acetate (Zytiga)(Prostate Cancer)(Wave 2) 2012 6/28/2012 \| published by: Decision Resources ... of Zytiga at 6 months, 1 year, and 1 year 6 months following the approval in the United States. LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products from launch ... \| read more...	$15,000.00
Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms 6/25/2012 \| published by: Decision Resources ... Japan). Demographic trends suggest an increase in the prevalent LUTS and BPH populations as a result of aging populations in the markets under study. Therapies for LUTS and BPH are very effective, but opportunity remains ... \| read more...	$15,000.00
ChartTrends®: Rheumatoid Arthritis in China 2012 6/21/2012 \| published by: Decision Resources ... data. ChartTrends® are syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing ... \| read more...	$15,000.00
Multiple Sclerosis in Europe: How Are Clinicians and Payers Responding to the Expanding Armamentarium of Disease-Modifying Therapies? 6/21/2012 \| published by: Decision Resources ... of therapeutic potential and treatment choice. Presently, a broad array of new and promising DMTs are advancing swiftly through the pipeline, including three late-stage products with near-term launch potential in Europe: Biogen Idec’s BG-12, Sanofi/Genzyme’s ... \| read more...	$10,000.00
Colorectal Cancer 6/19/2012 \| published by: Decision Resources ... will increase as the aging population continues to expand and patients continue to be identified through screening efforts throughout the major markets. Although in 2010 major-market sales of CRC treatments totaled more than $7 billion, ... \| read more...	$15,000.00
Prostate Cancer 6/19/2012 \| published by: Decision Resources ... as the standard of care for metastatic castrate-resistant prostate cancer (mCRPC) previously treated with docetaxel, but Medivation/Astellas Pharma’s enzalutamide (formerly MDV-3100) is poised to threaten its dominance in this setting. The mCRPC therapy market will ... \| read more...	$15,000.00
Renal Cell Carcinoma and Hepatocellular Carcinoma: How Will U.S. Payer and Physician Attitudes Impact Prescribing of Small-Molecule Oral Therapies? 6/18/2012 \| published by: Decision Resources ... based on a survey of 100 oncologists and 25 pharmacy directors (PDs) from MCOs that offer both commercial health insurance and Medicare Part D plans. A plethora of orally administered, small-molecule targeted drugs are available ... \| read more...	$10,000.00
TreatmentTrends®: Hepatitis C (US) (Wave 1) 2012 6/15/2012 \| published by: Decision Resources ... share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs. In addition, assessment of the impact of newer agents such as ... \| read more...	$15,000.00
TreatmentTrends®: Multiple Sclerosis (US) Q2 2012 6/15/2012 \| published by: Decision Resources ... the perspective of neurologists. TreatmentTrends® are syndicated report series that provide longitudinal information on market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate ... \| read more...	$15,000.00
Breast Cancer 6/13/2012 \| published by: Decision Resources ... cause of cancer-related death among women in the markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). The treatment of distinct subpopulations of CaB is addressed by numerous agents including hormonal ... \| read more...	$15,000.00
Glioblastoma (Newly Diagnosed): Avastin’s Future Hangs in the Balance as Oncologists Await Phase III Data—Which Other Emerging Drugs Excite Them? 6/4/2012 \| published by: Decision Resources ... namely Merck & Co.’s temozolomide (Temodar/Temodal, generics), have shown clinical benefits. Despite these advances in treatment, only moderate improvements in median overall survival (MOS) have been made for GBM patients and prognosis remains poor. The ... \| read more...	$10,000.00
DRG Insight: Hypertension (G7) 6/1/2012 \| published by: Decision Resources ... campaigns and initiatives. The hypertension market, though mature and heavily genericized, offers significant opportunities for blood pressure (BP)-lowering drugs that can prevent the development of cardiovascular disease, cerebrovascular disease, or end-organ damage. The best on-market ... \| read more...	$3,000.00

< prev 1 2 3 4 5 6 7 8 9 10 next >